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Results. There were no acute toxicity. Late toxicity were as follows: 20/25 patients had mild enteritis and 16/25 patients mild
rectitis. Overall and speciﬁc survival at 5 y was 40.6% and 48.8%. Local disease free survival at 5 y was 58.2%.
Conclusion. Hypofractionated irradiation is well tolerated. Short course radiotherapy, is a valid treatment option for patients unﬁt
for radiochemotherapy and for elderly patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.202
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Objective. The aim of this retrospective study was to assess the outcomes of hypofractionated treatment in patients with rectal
referred to our department.
Patients and methods. Between January 2002 and June 2012, 356 consecutive patients with pathologically conﬁrmed rectal cancer
were treated with neoadjuvant treatment in our department. We analyzed 19 patients treated with hypofractionated scheme.
The treatment schedule consisted of 3D conformal external radiotherapy hypofractionated (total dose of 25Gy in daily fractions
of 5Gy, 5 days per week) and surgery in the week immediately following the completion of radiotherapy.
Results. Gender: male 57.9%, female 42.1%. Median age was 78 years (range 50–85 years). Staging of the cancer was as follows:
31.6% M1, 42.1% N+ and 26.3% T3–T4N0. All patients completed the RT treatment without interruption and undergoing surgery
a week (2 AAP, 10 RAB, 2 Hartman, 3 palliative colostomies). With a median of follow-up of 11 months (range 1–33), OS at 1 and
2 years was of 64% and 55% respectively.The DFS at 1 and 2 years was 57% and 49%. Treatment was well tolerated presenting no
acute or chronic toxicity G3.
Conclusions. The standard treatment for advanced rectal cancer in our department is preoperative chemoradiation. In elderly
patients with comorbilities or metastatic disease the hypofractionated treatment is a good option. New studies indicate that
similar results are obtained with both schemes, with more cost effective and should be gradually incorporated into our practice.
http://dx.doi.org/10.1016/j.rpor.2013.03.203
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Introduction. The percentage of local relapse after radical treatment in rectal neoplasias is around 25%. 15% die without distant
disease and median survival without treatment is around 8 months. AIMS Assessment of recurrence treated with surgery plus
IOERT in our institution, in terms of locorregional control and toxicity.
Materials and methods. Retrospective study from March 2008 to January 2013 sixteen patients with rectal recurrence. They have
received IOERT as part of the rescue treatment. 37.5% are women and 62.5% men.The median age is 67 years (range 45–82 years).
The medium interval since the primary tumor is diagnosed to the recurrence is 20.71 months. 81.3% were asymptomatic to the
recurrence. Six of the sixteen patients examined received neoadjuvant radiotherapy (range 45–54Gy) and the other adjuvant
radiotherapy. The treatment volume was deﬁned by tumor size plus a margin that contains the area at risk; marked with surgical
clips for a correct display. The energy of electrons being used 9-15 MeV. The IOERT dose varies according to the surgical margin:
RO, R1, and R2 with 10, 12.5–15 and 17.5–20 respectively (90% isodose). Assessment of toxicity according to RTOG scale.
Results. With a follow-up of 58 months, the current overall survival of 68.8% is not statistically signiﬁcant (p=0.071) vs R0 vs
R2.The disease-free survival, distant and the local control is about 68.8%, 75% and 87.5%, respectively.The dominant pattern of
distant relapse: liver and lung. As for maximum acute toxicity was: grade II rectal 18.8%, moderate neuropathic pain 31.3% and
genitourinary in 18.8%. There were no late toxicity.
Conclusions. The use of IOERT in treatment of recurrent rectal can signiﬁcantly improve local control without increasing the
incidence and severity of toxicity. Individualized strategies and longer follow-up are needed.
http://dx.doi.org/10.1016/j.rpor.2013.03.204
